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Background & Aims 
 
Mutations in the hemochromatosis gene (HFE) (C282Y and H63D) lead to parenchymal iron accumulation, 
hemochromatosis, and liver damage. We investigated whether these factors also contribute to the 
progression of fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). 
 
Methods 
 
We studied clinical, histologic (liver biopsy samples for hepatocellular iron accumulation), serologic (iron 
and enzyme levels), and genetic (HFE genotype) data from 587 patients from Italy with NAFLD and 184 
control subjects. 
 
Results 
 
Iron accumulation predominantly in hepatocyes was associated with a 1.7-fold higher risk of a fibrosis stage 
greater than 1 (95% confidence interval [CI]: 1.2–2.3), compared with the absence of siderosis (after 
adjustment for age, body mass index, glucose tolerance status, and alanine aminotransferase level). 
Nonparenchymal/mixed siderosis was not associated with moderate/severe fibrosis (odds ratio, 0.72; 95% 
CI: 0.50–1.01). Hepatocellular siderosis was more prevalent in patients with HFE mutations than in those 
without; approximately one third of patients with HFE mutations had parenchymal iron accumulation 
(range, 29.8%–35.7%, depending on HFE genotype). Predominantly hepatocellular iron accumulation 
occurred in 52.7% of cases of patients with HFE mutations. There was no significant association between 
either the presence of HFE mutations or specific HFE genotypes and the severity of liver fibrosis. 
 
Conclusions 
 
Iron deposition predominantly in hepatocyes is associated with more severe liver damage in patients with 
NAFLD. However, HFE mutations cannot be used to identify patients with hepatocellular iron accumulation. 
 
Abbreviations used in this paper 
BMI, body mass index;  
GGT, γ-glutamyltranspeptidase;  
HFE, hemochromatosis gene;  
NAFLD, nonalcoholic fatty liver disease;  
NASH, nonalcoholic steatohepatitis 
 
 
 
Nonalcoholic fatty liver disease (NAFLD), characterized by hepatic1 and systemic2 and 3 insulin resistance 
and related to the metabolic syndrome,4 represents the leading cause of alterations of liver enzymes in 
Western countries, affecting 20%–34% of the population.5 and 6 In patients with severe insulin resistance 
and associated nonalcoholic steatohepatitis (NASH),4 NAFLD is a potentially progressive liver disease 
evolving to cirrhosis and eventually to hepatocarcinoma7, 8 and 9 and confers an increased risk of liver-
related mortality.10 Inherited factors play a role in the susceptibility to the metabolic syndrome and 
NASH,11 and single nucleotide polymorphisms in genes involved in inflammation, oxidative stress, and 
fibrogenesis have been associated with the severity of liver damage in NAFLD.12, 13 and 14 
 
Hyperferritinemia is observed in up to one third of NAFLD cases and has been associated with oxidative 
stress and mild hepatic iron accumulation15, 16 and 17 sometimes related to the presence of common 
mutations of the HFE gene responsible for hereditary hemochromatosis.16 and 18 Increased liver iron may 
directly promote fibrogenesis by inducing oxidative stress and stimulating hepatic stellate cells activation 
through ferritin release,19 but increased iron stores have also been shown to promote hepatic insulin 
resistance in rats fed with a high-fat diet.20 Moreover, iron depletion improved insulin resistance more 
than lifestyle changes alone in patients with NAFLD.17 
 
The C282Y and H63D mutations of the hemochromatosis gene (HFE) responsible for hereditary 
hemochromatosis represent the leading cause of inherited iron overload in individuals of European 
ancestry. 21 The mechanism is related to decreased hepcidin release leading to increased iron absorption 
and parenchymal deposition. 22 In white ethnicity patients with NAFLD, hyperferritinemia has been 
associated with more advanced liver damage, whereas the relationship between HFE mutations and liver 
fibrosis is controversial. 18, 23, 24, 25 and 26 Conflicting results are possibly related to several causes: (1) 
low number of patients considered in individual series, precluding the evaluation of the effect of single 
genotypes on liver damage; (2) different inclusion criteria; (3) lack of the estimate of the relationship 
between genotypic data and expression of iron overload; (4) different definition of HFE genotypes at risk 
for iron overload. The aim of this study was to determine the relationship among hepatocellular iron 
accumulation, HFE mutations, and liver damage in a large series of Italian patients with NAFLD. 
 
 
 
 
Patients and Methods 
 
Patients 
 
We considered 587 out of 680 (86.3%) unrelated white ethnicity patients from Italy with biopsy-proven 
NAFLD diagnosed between January 1999 and January 2008, whose DNA samples and complete clinical data 
were available. The cohort included 526 patients submitted to liver biopsy because of persistently 
abnormal liver enzymes/serum ferritin or a long-lasting history of steatosis associated with severe 
metabolic abnormalities and 61 severely obese patients who were found to be affected by NAFLD at 
routine liver biopsy performed during bariatric surgery. Ninety-three patients were excluded because of 
incomplete clinical data or lack of DNA samples; their clinical characteristics were not significantly different 
from the total cohort. Other causes of liver disease were previously used for exclusion, including increased 
alcohol intake (>30/20 g/day for males/females, respectively), as confirmed by at least 1 family member or 
friend and carboxydesialylated transferrin determination, autoimmune liver diseases, hereditary 
hemochromatosis (C282Y +/+ subjects), AAT deficiency, Wilson's disease, or viral hepatitis (Figure 1). Part 
of this group had previously been described.12 Because of the low penetrance of the C282Y/H63D 
genotype in the general population,21 subjects carrying this genotype were considered in this study. Body 
mass index (BMI) and metabolic parameters, including glucose and lipid levels, ferritin, and liver enzymes 
(aspartate aminotransferase [AST], alanine aminotransferase [ALT], and γ-glutamyltranspeptidase [GGT]), 
were available in all patients. Their demographic and clinical features are shown in Table 1. Subjects lacking 
the evaluation of histologic iron deposition (n = 107) were more often female, younger, and had a higher 
BMI because this subgroup included all the patients submitted to bariatric surgery (not shown in detail). 
The study was approved by the Institutional Review Board of the Ospedale Maggiore Policlinico IRCCS. 
 
  
Figure 1.  
Selection of the study patients. 
 
 
 
Table 1.  
Demographic and Clinical Features of 179 Italian Healthy Control Subjects With Normal Liver 
Enzymes and Metabolic Parameters and 587 Patients With Histologic Diagnosis of NAFLD 
 
Controls NAFLD, whole cohort NAFLD, siderosis available 
Number 179 587 480 
Sex (%) 38 (21) 77 (29) 88 (18) 
Age, y 48.4 ± 13 45.2 ± 11.6 46.1 ± 11.7 
BMI (kg/m2) 25.1 ± 2.7 29.0 ± 6.2a 27.3 ± 3.5a 
LDL cholesterol, mg/dL 118.7 ± 29 128.4 ± 43a 129.4 ± 43a 
HDL cholesterol, mg/dL 55.2 ± 13 44.9 ± 12a 48.1 ± 13a 
Triglycerides, mg/dL 90.1 ± 44 155.2 ± 84a 149.4 ± 88a 
Glucose, mg/dL 89.0 ± 10 98.3 ± 27a 98.8 ± 25a 
HOMA-IR 2.7 ± 1.6 4.3 ± 4.3a 4.4 ± 4.5a 
IGT-IFG/diabetes (%) 0/0 80 (14)/64 (11)a 72 (15)/46 (10)a 
ALT, UI/mL 21.8 ± 7 66.4 ± 41a 67.7 ± 47a 
GGT, UI/mL 23.7 ± 16 87.4 ± 104a 90.2 ± 102a 
Fibrosis stage 
F0/F1/F2/F3/F4 (%) 
— 270/166/82/45/24 (46/28/14/8/4) 232/112/69/43/24 (48/23/14/9/5) 
NOTE. Of 587 patients with histologic diagnosis of NAFLD, there were 480 available for re-
evaluation of histologic siderosis. 
HDL, high-density lipoprotein; HOMA-IR, homeostasis models assessment-insulin resistance; IGT, 
impaired glucose tolerance; IFG, impaired fasting glucose; LDL, low-density lipoprotein. 
a 
P < .0001 between patients and controls. 
 
 
Controls 
 
The control group included 184 Italian subjects from a larger series of 482 blood donors from Northern Italy 
without clinical and biochemical evidence of liver and metabolic disease and no alcohol abuse. We 
excluded subjects with ALT >35/30 IU/mL in males/females, GGT >35 IU/mL, BMI >28, abdominal 
circumference >100 cm, glucose levels ≥100 mg/dL, triglycerides ≥150 mg/dL, high-density lipoprotein 
≤45/55 in males/females, or a fatty liver index >40, a value with high specificity to rule out NAFLD in the 
general population.27 Informed written consent was obtained from each patient and control subject, and 
the study conforms to the ethical guidelines of the 1975 Declaration of Helsinki. 
 
Histologic Assessment 
 
Tissue sections were stained with H&E, impregnated with silver for reticulin framework, and stained with 
trichrome for collagen. Two expert pathologists unaware of clinical and genetic data reviewed all biopsy 
specimens for fibrosis stage and iron accumulation. The presence of NASH was assessed according to 
Kleiner et al.28 The minimum biopsy sample size was 1.7 cm and the number of portal areas was 10. 
Histologic re-evaluation of liver siderosis was performed in 480 samples according to Scheuer et al.29 
When detected, hepatic iron accumulation was defined as predominantly hepatocellular or 
nonparenchymal/mixed according to the prevalent distribution pattern of siderosis. 
 
Genetic Analysis 
 
DNA was extracted from peripheral blood by the phenol-chloroform method. Success rate in extracting 
DNA was 100% for each study group. The HFE genotype was genotyped by restriction analysis by personnel 
unaware of patients' clinical status. 14 Random samples were confirmed by direct genotyping that provided 
concordant results in all cases. Samples from both NAFLD patients and controls were included in all batches 
analyzed, and quality controls were performed to verify the reproducibility of the results. Valid genotypic 
data were obtained for over 99% of subjects analyzed. 
 
Statistical Analysis 
 
Our sample had a >90% power of detecting an odds ratio (OR) of 1.7 for fibrosis stage >1 in patients with 
NAFLD for the presence of HFE mutations, with a significance of 5% (2 tailed). Results are expressed as 
means ± standard deviation or median (interquartile range), when appropriate, and considered significant 
when P < .05 (2 tailed). Mean values were compared by analysis of variance or Wilcoxon test, when 
appropriate, and frequencies by χ2 test. 
The association between the HFE genotypes and the presence of metabolic abnormalities and fibrosis was 
evaluated by logistic regression analysis adjusted for confounders (as reported in the Results section). 
Analyses were carried out with JMP 6.0 statistical analysis software (SAS Institute Inc, Cary, NC). 
 
Results 
 
The frequency distribution of HFE genotypes was not significantly different (P = .6) between patients with 
NAFLD and controls with normal liver enzymes and metabolic parameters ( Table 2). The relationship 
between HFE genotypes and serum and histologic parameters of iron accumulation is shown in Table 3. In 
patients with NAFLD, the presence of HFE mutations was associated with significantly higher transferrin 
saturation levels compared with the wild-type (wt) genotype, and transferrin saturation was higher in 
patients carrying the C282Y/wt, H63D/H63D, and C282Y/H63D genotypes than in those carrying the 
H63D/wt genotype (P < .05). Ferritin levels and the prevalence of histologically detectable siderosis, in 
particular of nonparenchymal siderosis, were also significantly higher in patients carrying the C282Y/wt, 
H63D/H63D, and C282Y/H63D genotypes than in those carrying the H63D/wt and wt/wt genotypes. 
Similarly, hepatocellular siderosis was significantly more prevalent in patients carrying HFE mutations than 
in those who were negative but was expressed in 42.7%–76.5% of HFE mutations positive patients, 
depending on the genotype, and represented the predominant pattern of iron accumulation in 
approximately one third of them (range, 29.8%–35.7%). On the other hand, predominantly hepatocellular 
iron accumulation occurred in patients carrying HFE mutations in 52.7% of cases but only in 19.1% of cases 
in those positive for the C282Y/wt, H63D/H63D, and C282Y/H63D genotypes ( Figure 2). These 3 genotypes 
accounted for 22.8% of predominantly nonparenchymal iron accumulation. 
Table 2.  
Frequency Distribution of HFE Genotypes in 587 Italian Patients With NAFLD and 184 Healthy 
Subjects With Normal Liver Enzymes and Metabolic Parameters, P = .6 
 
HFE genotype 
 
 
wt/wt H63D/wt C282Y/wt H63D/H63D C282Y/H63D 
Patients, n = 587 (%) 367 (62.5) 152 (25.9) 34 (5.8) 19 (3.2) 15 (2.5) 
Controls, n = 184 (%) 114 (62.0) 53 (28.8) 8 (4.4) 7 (3.8) 2 (1.1) 
Adjusted ORa Reference 0.65 1.37 0.70 2.42 
95% CI Reference 0.40−1.03 0.63−3.16 0.30−1.75 0.82−11.02 
a 
Adjusted for age, sex, and BMI. 
Table 3.  
Effect of HFE Genotypes on Serum Iron Parameters in 587 Italian Patients With NAFLD and of 
Hepatic Siderosis in 480 Patients 
 
HFE genotype 
 P 
value 
wt/wt (n = 
367) 
H63D/wt (n = 
152) 
C282Y/wt (n 
= 34) 
H63D/H63D 
(n = 19) 
C282Y/H63D 
(n = 15) 
Serum iron parameters in 587 NAFLD patients 
 Ferritin (ng/mL) 
223 {123–
530} 
266 {128–
580} 
532 {168–
784}a 
545 {169–
715}a 
458 {298–515}a .005 
 Transferrin 
saturation (%) 
32.8 ± 11.7 35.9 ± 13.7a 40.7 ± 13.7a 39.0 ± 12a 38.7 ± 8.8a .0007 
Hepatic siderosis, 
480 patients 
wt/wt (n = 
292) 
H63D/wt (n = 
124) 
C282Y/wt (n 
= 33) 
H63D/H63D 
(n = 17) 
C282Y/H63D 
(n = 14)  
 Hepatocellular 
siderosis (%) 
95 (32.5) 53 (42.7) 15 (45.5) 13 (76.5)a 9 (64.3)a .0004 
 Kupffer cell 
siderosis (%) 
79 (27.1) 33 (26.6) 15 (45.5)a 11 (64.7)a 8 (57.1)a .0005 
 Overall siderosis 
grade >2 
108 (29.4) 49 (32.2) 18 (52.9)a 14 (73.9)a 12 (75.0)a <.0001 
Siderosis pattern 
     
<.0001 
 No siderosis 168 (57.5) 64 (51.6) 12 (36.4)a 2 (11.8)a 1 (7.1)a <.0001 
 Hepatocellular 52 (17.8) 37 (29.8)a 9 (27.3) 7 (41.2)a 5 (35.7) .01 
 Nonparenchymal 72 (24.7) 23 (18.6) 12 (36.4) 8 (47.0) 8 (57.2)a .002 
NOTE. Results are expressed as mean ± standard deviation except that for ferritin, where median 
{interquartile range} is reported. 
a 
P < .05 vs wt/wt. 
 
 
 
 
 Figure 2.  
Penetrance of predominantly parenchymal iron overload (ie, the percentage of subjects with a given HFE genotype presenting 
with predominantly parenchymal iron accumulation) and relative contribution to the whole burden of predominantly 
parenchymal iron accumulation (ie, the percentage of subjects with predominantly parenchymal iron accumulation attributable 
to a given HFE genotype) in 480 patients with NAFLD subdivided according to HFE genotypes. Wt, wild-type. 
 
 
 
The sensitivity and specificity of predominantly parenchymal iron accumulation according to the presence 
of HFE mutations were 52.7% and 64.8%, respectively. The association between the presence and pattern 
of hepatic iron accumulation and moderate/severe fibrosis (stage >1) adjusted for other risk factors (age, 
BMI, presence of diabetes, and ALT levels) is shown in Table 4. The presence of predominantly 
hepatocellular iron accumulation was associated with a 1.68-fold higher risk of fibrosis >1 (95% confidence 
interval [CI]: 1.2–2.3) compared with the absence of detectable siderosis, an amount of risk very similar to 
that conferred by the presence of diabetes and prediabetes. In contrast, the presence of predominantly 
nonparenchymal siderosis was not associated with increased fibrosis >1, with an OR nearly associated with 
a protective effect (OR, 0.72; 95% CI: 0.5–1.01). 
 
 
Table 4.  
Independent Predictors of Fibrosis >1 at Logistic Regression Analysis in 480 Patients With NAFLD 
With Histologic Characterization of Hepatic Iron Deposition 
 
Odds ratio 95% CI P value 
Age, y 1.023 1.003–1.044 .023 
BMI (kg/m2) 1.093 1.029–1.162 .004 
 
Odds ratio 95% CI P value 
Diabetes/IFG/IGT 1.579 1.243–2.005 .0002 
ALT, IU/mL 1.011 1.007–1.016 <.0001 
Siderosis pattern 
   
 None Reference — — 
 Hepatocellular 1.684 1.210–2.343 .002 
 Nonparenchymal 0.719 0.503–1.011 .063 
IFG, impaired fasting glucose; IGT, impaired glucose tolerance. 
 
At logistic regression analysis adjusted for age, BMI, presence of hyperglycemia, and ALT levels, fibrosis >1 
was also associated with higher transferrin saturation (OR, 1.017 for each unit increase in percentage 
transferrin saturation, 95% CI: 1.001–1.034; P = .033), known to be associated with parenchymal iron 
deposition, but not with ferritin levels (OR, 1.003; 95% CI: 0.999–1.001; P = .33), reflecting both 
parenchymal and nonparenchymal iron accumulation, or the global severity of histologic siderosis 
independently of iron compartmentalization (OR, 1.089; 95% CI: 0.911–1.296; P = .346). 
 
At univariate analysis, both hepatocellular and nonparenchymal siderosis were significantly associated (P < 
.05) with male sex, higher transferrin saturation percentage, higher serum ferritin, and lower ALT levels 
(not with BMI levels). Hepatocellular siderosis was also significantly associated with lower platelets levels, 
higher total bilirubin, and lower percentage of hepatocytes with fat droplets. Nonparenchymal siderosis 
was also significantly associated with older age and higher platelet levels ( Table 5). Serum ferritin was 
significantly higher in patients with nonparenchymal than in those with predominantly parenchymal iron 
deposition (P < .05). 
Table 5.  
Clinical Variables Associated With the Pattern of Hepatic Iron Accumulation in 480 Italian Patients 
With NAFLD 
 
Hepatic iron deposition 
 P value 
 
Hepatocellular (n = 110) Nonparenchymal (n = 123) None (n = 247) 
Age, y 46.3 ± 11 48.9 ± 11a 44.6 ± 11 .003 
Sex, F 15 (13.6)a 17 (13.8) 56 (22.7) .040 
Transferrin saturation, % 37.5 ± 14a 38.9 ± 11a 30.9 ± 12 <.0001 
Ferritin, ng/mL 354 {177–578}a 606 {399–832} 166 {89–289} <.0001 
ALT, IU/mL 60.9 ± 35a 61.3 ± 45a 74.0 ± 52 .014 
 Hepatic iron deposition 
 P value 
 
Hepatocellular (n = 110) Nonparenchymal (n = 123) None (n = 247) 
Platelets, 103/dL 119.5 ± 113a 187.8 ± 97a 170.8 ± 112 <.0001 
Bilirubin, mg/dL 1.03 ± 0.5a 0.96 ± 0.5 0.84 ± 0.5 .008 
Steatosis, % b 24.8 ± 22a 36.1 ± 24 34.1 ± 27 .026 
NOTE. Results are expressed as mean ± standard deviation except that for ferritin, where median 
{interquartile range} is reported. 
a 
P < .05 vs patients without iron deposition. 
b 
Percent of fat-laden hepatocytes evaluated on histologic sections. 
 
 
Because HFE mutations predispose to hepatic iron accumulation and predominantly parenchymal iron 
accumulation was independently associated with the presence of moderate/severe fibrosis, we next 
determined whether HFE mutations predisposed to liver damage. HFE genotypes were not significantly 
associated with demographic, anthropometric, metabolic features, and liver enzymes in this series. The 
prevalence of liver fibrosis stage >1 and >2 according to HFE genotypes is shown in Figure 3A. There was no 
significant association between HFE genotype, either considering each separate genotype or only the 
presence of C282Y and H63D mutations, and the severity of liver fibrosis in the whole series of subjects 
analyzed, as well as in the 480 subjects in whom the evaluation of hepatic siderosis was available (not 
shown in detail). Also restricting the analysis to subjects with BMI <30 or <27.5 kg/m2, HFE genotype was 
not associated with fibrosis >1, whereas parenchymal siderosis was significantly associated with fibrosis >1 
in these subgroups. The prevalence of fibrosis >1 was higher in patients with hepatocellular iron 
accumulation independent of the HFE genotype ( Figure 3B). 
 
 Figure 3.  
(A) Prevalence of fibrosis stage >1 and >2 in 587 Italian patients with NAFLD subdivided according to the HFE genotype. Wt, 
wild-type. (B) Prevalence of fibrosis stage >1 in 480 Italian patients with NAFLD subdivided according to the presence/pattern 
of hepatic iron deposition and the presence of the H63D or C282Y HFE mutations. *P < .05 vs patients positive for HFE 
mutations and predominantly hepatocellular iron deposition. 
 
Discussion 
 
Altered iron parameters are frequently detected in patients with NAFLD,16 and parenchymal iron 
accumulation is a well-recognized and treatable determinant of liver damage in patients with hereditary 
hemochromatosis.22 Because HFE mutations are the main cause of hemochromatosis and parenchymal 
iron accumulation in white ethnicity individuals,21 several studies have investigated the role of the 
common C282Y and H63D HFE genetic variants in the progression of liver damage in NAFLD, which has a 
strong genetic component. 11 
 
Conflicting data have been reported on the role of HFE mutations on liver damage in NAFLD. Some studies 
suggested an association between the presence of the C282Y mutation and other HFE genotypes 
predisposing to iron overload with more severe liver damage, 26 and 30 whereas others did not detect any 
effect on the severity of liver fibrosis. 
 
In the present study, we found that hepatocellular, but not nonparenchymal iron deposition, was a risk 
factor for moderate/severe fibrosis independently of confounding variables in a large series of Italian 
patients with NAFLD. These findings are in line with previous results26 and 30 and fit well with the known 
association between the severity and duration of parenchymal iron overload and the progression of liver 
fibrosis in patients with hereditary hemochromatosis, as well as with the lack of any association between 
nonparenchymal iron accumulation because of mutations inactivating the iron exporter ferroportin and 
liver fibrosis.22 and 31 
 
However, different from our results, in a large multiethnic series of NAFLD patients from the United States, 
Nelson et al have recently presented preliminary results indicating that nonparenchymal, but not 
predominantly hepatocellular, iron accumulation was independently associated with more advanced liver 
damage.32 Unfortunately, the genetic characterization of these subjects was not reported. The apparent 
discrepancy in the association between the pattern of iron overload and fibrosis may be at least partially 
explained by ethnic differences because of different genetic factors responsible for iron overload and 
fibrosis and by the significantly lower body mass observed in US patients with predominantly parenchymal 
iron accumulation. Interestingly, we also observed a nonsignificant trend for lower BMI and steatosis 
percentage and lower ALT levels in patients with predominantly parenchymal iron accumulation. 
 
Even though HFE mutations increased the risk of parenchymal iron accumulation, they were not associated 
with liver damage. The most likely explanation of these findings is related to the weak association between 
HFE mutations and hepatocellular iron deposition. Indeed, only 30%–41% of patients carrying HFE 
mutations had phenotypically expressed predominantly parenchymal iron accumulation, as compared with 
18% of subjects negative for HFE mutations, and 47% of patients with predominantly hepatocellular iron 
accumulation did not carry HFE mutations. These data are not surprising because it has recently been 
recognized that the penetrance of HFE mutations, even that of homozygosity for the C282Y, is very low, 
with as few as 1%–20% of affected individuals developing overt liver disease. 33 Thus, based on the data 
obtained in the general population, we did not expect a high penetrance of certain HFE genotypes, such as 
heterozygosity for the H63D and C282Y mutations, on parenchymal iron accumulation. 21 
 
NAFLD by itself was reported to predispose to liver iron accumulation,34 but, as confirmed in this series, 
the most typical patterns are either nonparenchymal or mixed hepatic iron deposition, which may be 
related to liver cell necrosis, inflammation, altered cytokines release (possibly the cause of higher platelet 
count in patients with nonparenchymal iron deposition), and down-regulation of protein involved in cellular 
iron export.35 Unexpectedly, nonparenchymal iron deposition was more common than hepatocellular iron 
deposition in subjects with HFE genotypes at risk, further contributing to the lack of association between 
HFE mutations and more advanced liver damage. Thus, as in hereditary hemochromatosis, additional, 
possibly ethnic-specific, largely unknown genetic factors are likely to modify the penetrance of HFE 
mutations on parenchymal iron accumulation in NAFLD and to contribute to parenchymal iron deposition in 
patients negative for HFE mutations. 
 
As an example, it was previously reported in a subset of this series14 that α1-antitrypsin mutations induced 
a shift in the pattern of iron accumulation toward nonparenchymal cells and were protective against 
parenchymal iron accumulation and liver fibrosis in patients carrying HFE mutations. Furthermore, it is 
possible that hemoglobin defects play a role because, in Italy, the β-thalassemia trait was associated with 
hepatic iron accumulation (because of ineffective erythropoiesis, suppression of hepcidin release, and 
increased iron absorption) and liver fibrosis in patients with chronic HCV infection. 36 The higher total 
bilirubin levels observed in patients with hepatocellular siderosis may be due to ineffective erythropoiesis 
or to more severe liver disease, in line with the higher severity of fibrosis and lower platelet count. 
However, the HFE modifier genes hypothesis needs to be proven in further studies, and a majority of the 
involved genes are probably still unknown. 
Despite the aforementioned limitations, this study also has strengths. It considers a case series much larger 
than any previous one, recruited in different centers from Northern Italy, of which only 1 represented a 
referral center for iron overload disorders, with a genetically homogenous background. A DNA sample and 
consent for determination of HFE genotype were available for the majority of subjects submitted to liver 
biopsy at the different centers, the characterization of serum iron parameters was available for all patients, 
and there was a blinded re-evaluation of hepatic siderosis for a large majority of them. 
 
In conclusion, only predominantly hepatocellular iron deposition is associated with more severe liver 
damage in Italian patients with NAFLD. However, HFE genotype determination is not clinically useful in 
these patients, unless evidence of severe parenchymal iron accumulation has been obtained, because by 
itself it is not sufficient to identify patients with hepatocellular iron. Additional studies are required to 
evaluate the role of HFE modifier genes on iron metabolism and liver damage in patients with NAFLD. 
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This article has an accompanying continuing medical education activity on page e9. Learning Objective: 
Upon completion of reading this article, successful learners will be able to differentiate the effect of 
different patterns of iron overload on liver damage, understand the effect of mutations in the HFE gene of 
hereditary hemochromatosis in determining the predisposition to develop iron overload, and recognize the 
lack of utility of HFE mutations assessment in the absence of histological demonstration of hepatocellular 
iron accumulation in patients with nonalcoholic fatty liver disease. 
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